The FDA's Day 60 filing decision on December 27, 2026 will determine whether the NDA is accepted for review and whether priority review is granted. The mixed Phase 3 results (missed primary endpoint but positive prespecified subgroup) create regulatory uncertainty. Monitor the filing decision and any advisory committee briefing documents for the FDA's view on the efficacy data.
Drug in focus
RFL drug pipeline →remibetadex
◆ Mixed Named in this 8-K- Impact
- Phase
- Filed/PDUFA (NDA submitted)
- Time to market
- If the FDA accepts the NDA for filing, a standard review would take 10 months from filing acceptance, with a potential PDUFA date in late 2027. Priority review (if granted) could shorten this to 6-8 months. The FDA has 60 days from the October 28 submission to decide on filing acceptance.
- Next catalyst
- None dated
What to watchThe next catalyst is the FDA's filing decision within approximately 60 days (by late December 2026). If the NDA is accepted, a PDUFA target action date will be assigned. If rejected, the stock could face significant downside given the Phase 3 primary endpoint miss. Watch for any financing announcements given the $22.1M cash balance and ongoing burn rate.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $1.07entry
- T+1 · 6d ago +1.87%α +0.55% · $1.09
- T+4 · todayOpen
- T+5 · in 5h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rafael Holdings filed an 8-K furnishing an investor presentation that reviews Phase 3 topline data for remibetadex in Niemann-Pick disease type C (NPC). The primary endpoint was not statistically significant (p=0.19), but a prespecified analysis in patients on miglustat/leucine showed a 71% relative slowing of disease progression (p=0.046). An NDA was submitted to the FDA in October 2026 with a potential PDUFA target around mid-2027 if priority review is granted.
Key Facts
- Phase 3 TransportNPC primary endpoint (4DNPCSS change at Week 96) not statistically significant: difference 0.81, p=0.19
- Prespecified analysis in patients on miglustat/leucine (n=78) showed 71% relative slowing of disease progression, difference 1.11, p=0.046
- NDA submitted to FDA in October 2026; Day 60 filing decision expected Dec. 27, 2026
- Potential PDUFA target date ~June 2027 if priority review granted
- Cash balance of approximately $22.1M as of July 31, 2026
- Company evaluating financing and strategic options for NDA review and launch
- Rare Pediatric Disease PRV program extended to September 2029; recent four vouchers sold for average ~$200M
- Serious TEAEs occurred more frequently with remibetadex (35.9%) vs placebo (16.7%)
Financial Impact
No revenue or earnings reported; $22.1M cash balance; potential commercial opportunity in NPC market expected to exceed $920M by 2033
Risk Factors
- Phase 3 primary endpoint was not statistically significant, which may complicate FDA review
- Company has substantial doubt about ability to continue as a going concern and needs additional capital
- FDA may not accept the NDA for filing, grant priority review, or approve remibetadex
- Serious adverse events were more frequent in the remibetadex arm (35.9% vs 16.7%)
- Remibetadex has not received regulatory approval and may never be commercialized
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-117552 |
| Document: ea0311540-8k_rafael.htm | 0001213900-26-117552 |
| Document: 0001213900-26-117552-index-headers.html | 0001213900-26-117552 |
| Document: 0001213900-26-117552-index.html | 0001213900-26-117552 |
| Document: 0001213900-26-117552.txt | 0001213900-26-117552 |
Track record
12 reports on RFL
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today DEF 14A Neutral 3/10 Entry $1.08 Now $0.9700 −10.19% settles Feb 12
- Nov 9, 20267d ago 8-K Neutral 5/10 Viewing Entry $1.07 Now $0.9700 −9.35% settles Feb 8
- Oct 29, 202618d ago 8-K Neutral 6/10 No price data
- Oct 29, 202618d ago Press Release Neutral 5/10 Entry $1.12 Now $0.9700 −13.39% settles Jan 27
- Sep 30, 20266w ago 8-K Mixed 7/10 Entry $1.32 Now $0.9700 −26.52% settles Dec 24
- Sep 30, 20266w ago Press Release Mixed 7/10 Entry $1.32 Now $0.9700 −26.52% settles Dec 24
- Aug 18, 202612w ago Institutional Cluster Bullish 6/10 Entry $1.86 to $1.07 Now $0.9700 −47.85% ▼ −42.47% −40.43% vs SPY
- Jun 11, 202622w ago 8-K Mixed 7/10 Entry $2.12 to $2.56 Now $0.9700 −54.25% ▲ +20.75% +16.36% vs SPY
- Jun 10, 202622w ago 8-K Neutral 5/10 Entry $1.78 to $2.47 Now $0.9700 −45.51% ▲ +38.76% +32.18% vs SPY
- Jun 10, 202622w ago Press Release Bullish 7/10 Entry $1.78 to $2.47 Now $0.9700 −45.51% ▲ +38.76% +32.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers